Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients

Launched by HELWAN UNIVERSITY · Jul 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well two medications, acetazolamide and dapagliflozin, work when added to standard treatment for patients with acute decompensated heart failure (ADHF). ADHF occurs when the heart can't pump enough blood, leading to symptoms like swelling and shortness of breath. The trial aims to find out which medication helps reduce a specific heart-related protein in the blood and which one is more effective at helping patients lose excess fluid, measured by weight loss.

To participate, you need to be an adult (18 years or older) who has been admitted to the hospital with signs of heart failure and fluid overload, such as swelling or fluid in the lungs. Participants will take one of the medications daily for three days while receiving standard treatment, including intravenous diuretics (medications that help remove excess fluid). Throughout the study, patients will be monitored for their heart failure symptoms, weight changes, and other health tests until they leave the hospital and for 30 days after starting the trial. This research will help doctors understand better treatment options for patients with this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients of 18 years of age or older.
• • An elective or emergency hospital admission with clinical diagnosis of decompensated HF with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).
• • Assessed LVEF by any imaging technique; i.e. echocardiography, catheterization, nuclear scan magnetic resonance imaging within 12 months of inclusion.
• Exclusion Criteria:
• • The receipt of acetazolamide maintenance therapy.
• • Receipt of an SGLT2 inhibitor in the 48 hours before randomization.
• • An estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73 m2.
• • Use of any non-protocol defined diuretic agent with the exception of mineralocorticoid receptor antagonists during the treatment phase of the study. Thiazides, metolazone, indapamide and amiloride should be stopped upon study inclusion. If patient is taking a combination drug including a thiazide-type diuretic, the thiazide-type diuretic should be stopped.